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Objective: This meta-analysis aimed to examine the impact of anti-
pyretic therapy on mortality in critically ill septic adults.
Data Sources: Literature searches were implemented in Ovid 
Medline, Embase, Scopus, Cumulative Index of Nursing and 
Allied Health Literature, Cochrane Central Register of Controlled 
Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov 
through February 2016.
Study Selection: Inclusion criteria were observational or random-
ized studies of septic patients, evaluation of antipyretic treatment, 
mortality reported, and English-language version available. Stud-
ies were excluded if they enrolled pediatric patients, patients with 
neurologic injury, or healthy volunteers. Criteria were applied by 
two independent reviewers.
Data Extraction: Two reviewers independently extracted data 
and evaluated methodologic quality. Outcomes included mortal-
ity, frequency of shock reversal, acquisition of nosocomial infec-
tions, and changes in body temperature, heart rate, and minute 
ventilation. Randomized and observational studies were analyzed 
separately.
Data Synthesis: Eight randomized studies (1,507 patients) and 
eight observational studies (17,432 patients) were analyzed. 
Antipyretic therapy did not reduce 28-day/hospital mortality in 
the randomized studies (relative risk, 0.93; 95% CI, 0.77–1.13; 
I2 = 0.0%) or observational studies (odds ratio, 0.90; 95% CI, 
0.54–1.51; I2 = 76.1%). Shock reversal (relative risk, 1.13; 95% 
CI, 0.68–1.90; I2 = 51.6%) and acquisition of nosocomial infec-
tions (relative risk, 1.13; 95% CI, 0.61–2.09; I2 = 61.0%) were 
also unchanged. Antipyretic therapy decreased body temperature 
(mean difference, –0.38°C; 95% CI, –0.63 to –0.13; I2 = 84.0%), 
but not heart rate or minute ventilation.
Conclusions: Antipyretic treatment does not significantly improve 
28-day/hospital mortality in adult patients with sepsis. (Crit Care 
Med 2017; 45:806–813)
Key Words: acetaminophen; antipyretics; fever; mortality; sepsis
Over 1 million patients are hospitalized with sepsis annually in the United States, and sepsis is the lead-ing cause of death in critically ill patients (1). Fever, 
a common sign of infection, occurs in approximately 40% of 
critically ill septic patients at some point during their ICU stay 
(2, 3). It is an extremely complex physiologic response with 
potentially beneficial and harmful effects in septic patients. 
Fever boosts several aspects of innate and adaptive immunity, 
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inhibits microorganism growth, slows viral replication, and 
augments antibiotic efficacy (4–8). In animal models, artifi-
cially raising core body temperature leads to improved survival 
and lower infectious burden (9, 10). However, fever genera-
tion also raises the metabolic rate, increases oxygen consump-
tion, and can adversely affect cardiac function (11–13). In 
septic patients, who are vulnerable to malperfusion and tis-
sue hypoxia, this physiologic expense could be particularly 
detrimental.
Despite the potential benefits of fever in patients with sepsis, 
treatment with antipyretic therapies is common in the ICU. In a 
recent international survey of ICU practitioners in 23 countries, 
greater than 80% of respondents reported controlling fever in 
critically ill patients most or all of the time (14). Data support-
ing this practice, however, remain inconclusive because of lim-
ited sample sizes and lack of reproducibility of study results. In 
fact, some studies have suggested that antipyresis in critically ill 
septic patients may be harmful (15–17). The majority of prior 
meta-analyses of the effect of antipyretic therapy in the critically 
ill have not focused on septic patients (18–20). Because anti-
pyretic therapy may impact infected and noninfected patients 
differently (16), conclusions from these studies are difficult to 
interpret. Furthermore, methodologic limitations in previous 
evaluations of antipyretic therapy in sepsis render the question 
of optimal fever management in this population unclear (21).
The objective of this meta-analysis was to evaluate the effect 
of antipyretic therapy on mortality in critically ill septic patients. 
Secondary aims included assessing the impact of fever control 
on the acquisition of nosocomial infections, shock reversal, and 
physiologic variables such as body temperature, heart rate, and 
minute ventilation. The primary hypothesis was that antipyretic 
therapy would not improve mortality in septic patients.
MATERIALS AND METHODS
This meta-analysis was conducted and reported in accordance 
to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis and Meta-Analysis of Observational Studies in 
Epidemiology guidelines (Supplemental Digital Content 1, 
http://links.lww.com/CCM/C421) (22, 23). The study proto-
col (Supplemental Digital Content 2, http://links.lww.com/
CCM/C422) was developed prior to initiation of the search 
strategy and has been registered on PROSPERO (registration 
number: CRD42016037622). Ethical approval from the human 
research protection office was not required.
Literature Search and Study Selection
Published literature was electronically searched by two medi-
cal librarians (A.C.H., S.A.F.) for the concepts of sepsis, fever, 
antipyretics, and physical cooling in adults. These strategies 
were implemented in Ovid Medline, Embase, Scopus, Cumu-
lative Index of Nursing and Allied Health Literature, Cochrane 
Database of Systematic Reviews, Cochrane Central Register of 
Controlled Trials, NHS Economic Evaluation Database, and 
ClinicalTrials.gov between January 1946 and February 2016. 
Full search strategies are provided in Supplemental Digital 
Content 3 (http://links.lww.com/CCM/C423).
Two authors (A.M.D., E.T.M.) independently screened titles 
and abstracts for potentially eligible studies. These included 
observational or randomized studies evaluating mortality in 
septic patients treated with and without antipyretic therapy. 
The full list of inclusion and exclusion criteria is available in 
Supplemental Digital Content 4 (http://links.lww.com/CCM/
C424). Studies of antipyretic therapy that included both sep-
tic and nonseptic patients were included if mortality data were 
provided for the subgroup of septic patients. If these data were 
not reported, authors were contacted via electronic mail to 
request it. The authors (A.M.D., E.T.M.) also reviewed bibli-
ographies of included articles and performed a hand search 
of critical care–related journals to identify additional studies. 
Abstracts from critical care–related meetings (full list provided 
in the protocol) from 2008 to 2015 were searched to identify 
any unpublished literature. Any article identified by either 
screener as being potentially eligible was reviewed in full.
Following the initial screening, full articles were inde-
pendently reviewed by two authors (A.M.D., B.M.F.) with 
application of the same inclusion and exclusion criteria. 
Disagreements regarding study inclusion were resolved by 
consensus. Studies excluded after full-text review are listed 
in Supplemental Table 1 (Supplemental Digital Content 5, 
http://links.lww.com/CCM/C425).
Data Extraction
Data on study characteristics, patient characteristics, study 
interventions, and outcomes were independently extracted 
from each study by two study members (A.M.D., E.A.A.) using 
standardized forms created in an online data management sys-
tem (24). A full list of variables collected is provided in Supple-
mental Digital Content 2 (http://links.lww.com/CCM/C422). 
Primary data reported solely in graphical form were extracted 
using an online plot data extraction tool (25). When neces-
sary, authors were contacted to provide missing data. Follow-
ing extraction, data were compared and disagreements were 
resolved by consensus.
Outcomes
The primary outcome was 28-day mortality. Studies reporting 
hospital mortality were pooled with those reporting 28-day 
mortality. Secondary outcomes included “early” mortality 
(defined as mortality on or prior to day 14 after enrollment or 
within the ICU), frequency of acquisition of nosocomial infec-
tions, frequency of shock reversal, and mean changes in body 
temperature, heart rate, and minute ventilation with antipyretic 
treatment. A priori, the decision was made to analyze 28-day and 
14-day mortality separately based on observations of different 
mortality rates for these different follow-up periods (26, 27). 
For randomized trials, postintervention physiologic values were 
pooled for meta-analysis rather than the pre- to postchange in 
those values because no study provided measures of dispersion 
for the pre- to postintervention changes. This was considered to 
be a valid approach based on the assumption that in random-
ized trials, the differences in mean final values are similar to the 
differences in changes of these values (28).
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Quality Assessment
For randomized trials, study quality was assessed independently 
by two reviewers (A.M.D., E.A.A.) using the Cochrane Collabo-
ration Risk of Bias Tool with standardized criteria for evaluating 
bias in seven domains (29). Quality of observational studies was 
evaluated with the Newcastle-Ottawa Scale (NOS), a 9-point 
scale assessing bias in the areas of patient selection, comparabil-
ity, exposure, and outcome (30). Disagreements were resolved 
by a third reviewer (B.M.F.). A priori, it was decided that ran-
domized studies with a high or unclear risk of bias in less than 
two domains or observational studies with an NOS score greater 
than 7 would be considered to be high quality.
Data Analysis
Observational and randomized studies were analyzed sepa-
rately, as recommended by expert opinion (31), using STATA/
IC 14.1 (StataCorp, College Station, TX). For categorical 
outcomes, a relative risk (RR) with 95% CI (for randomized 
studies) or odds ratio (OR) with 95% CI (for observational 
studies) was calculated for each study. Data were combined 
using the DerSimonian and Laird (32) random effects model 
and plotted as forest plots. Higgins I2 tests were used to assess 
heterogeneity. A random effects model was used even if no 
heterogeneity was observed due to limitations of statistical 
tests for heterogeneity. For observational studies, adjusted 
ORs, if available, were preferentially used in the meta-analysis. 
For studies evaluating multiple methods of antipyresis, the 
overall OR for any type of antipyresis was used in the meta-
analysis. However, if an overall OR was not reported, ORs 
for each method of antipyresis were included separately. For 
continuous outcomes, weighted mean differences were calcu-
lated using a random effects model for continuous outcomes. 
For continuous data reported 
as median and interquartile 
range, mean and sd were esti-
mated using previously pub-
lished methods (33). A p value 
less than 0.05 was considered 
statistically significant.
Publication bias was 
assessed using funnel plots 
and Egger test. Extended 
funnel plots were created to 
graphically display the effect 
size and se combinations 
needed for an additional ran-
domized trial to change the 
results of the meta-analysis 
(34, 35). Simulation methods 
were used to create a graph 
demonstrating the power 
achieved by an additional ran-
domized trial to change the 
results of the meta-analysis at 
different sample sizes up to a 
maximum of 30,000 patients 
(36, 37).
Stratified analyses were 
conducted for the primary 
outcome by the type of inter-
vention, duration of treat-
ment, and primary goal of 
the study (evaluation of 
anti-inflammatory treatment 
or evaluation of fever treat-
ment). Predefined subgroup 
analyses for the primary out-
come were performed for the 
subset of studies with a low 
risk of bias and for the sub-
set of patients with fever and 
septic shock.Figure 1. Flowchart of study selection.
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RESULTS
Details regarding the literature search and study selection are 
shown in Figure 1. A total of 16 studies (eight randomized 
studies and eight observational studies) met eligibility criteria 
(15, 16, 26, 27, 38–49). Study characteristics are shown in Sup-
plemental Table 2 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425).
Randomized Trials
The randomized studies enrolled a total of 1,531 patients 
(1,507 patients included in analysis of the primary outcome). 
Patient characteristics and outcome data for the individual tri-
als are shown in Supplemental Tables 3 and 4 (Supplemental 
Digital Content 5, http://links.lww.com/CCM/C425). Risk of 
bias assessments are shown in Supplemental Table 5 (Supple-
mental Digital Content 5, http://links.lww.com/CCM/C425). 
Five studies had a low risk of bias.
Results of the meta-analyses for the primary and second-
ary outcomes are listed in Table 1. Four studies (1,198 patients) 
reported 28-day mortality with a pooled RR of 0.93 (95% CI, 
0.77–1.13; I2 = 0.0%) comparing antipyretic therapy to control. 
The remaining four studies reported hospital mortality; adding 
this data to the analysis (1,507 total patients) resulted in a pooled 
RR of 0.93 (95% CI, 0.79–1.09; I2 = 0.0%) (Fig. 2). Subgroup 
analyses of 28-day/hospital mortality in febrile patients (RR, 
0.96; 95% CI, 0.80–1.14; I2 = 0.0%) and patients with shock 
(RR, 0.91; 95% CI, 0.74–1.11; I2 = 0.0) yielded similar results. 
Stratified analyses by type of therapy and treatment goal also did 
not differ significantly from that of the aggregate data (Table 1).
Analyses of secondary outcomes (Table 1) showed a signifi-
cant decrease in early mortality (RR, 0.68; 95% CI, 0.49–0.92; 
I2 = 0.0%) with antipyretic therapy. Postintervention body tem-
perature was also significantly lower (mean difference, –0.38°C; 
95% CI, –0.63 to –0.13; I2 = 84.0%) in patients treated with 
antipyretics. Stratified analysis of postintervention body tem-
perature by type of intervention showed that physical cooling 
and nonsteroidal anti-inflammatory drugs (NSAIDs) lowered 
body temperature (mean difference, –0.80°C; 95% CI, –1.06 
to –0.54 and mean difference, –0.59°C; 95% CI, –1.16 to –0.03; 
I2 = 85.4%) more effectively than acetaminophen (mean differ-
ence, –0.14°C; 95% CI, –0.37 to 0.10; I2 71.3%). However, only 
one study used physical cooling as the primary antipyretic inter-
vention. Postintervention heart rate and minute ventilation were 
not significantly different between the groups. The frequency of 
nosocomial infections and shock reversal were also unchanged 
(forest plots shown in Supplemental Figs. 1–3, Supplemental 
Digital Content 5, http://links.lww.com/CCM/C425).
Publication bias was not evident (Egger test, p = 0.60) 
(Supplemental Fig. 4, Supplemental Digital Content 5, http://
links.lww.com/CCM/C425). The extended funnel plot, which 
graphically demonstrates the combinations of effect size and 
se that would be required for an additional study to change the 
results of this meta-analysis to support a 28-day/hospital mor-
tality benefit with antipyretic therapy, is shown in Figure 3. 
Supplemental Figure 5 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425) shows the power curve generated 
from simulation-based sample size calculations. To achieve a 
power of 80% to change the results of this meta-analysis, an 
additional study would require a total sample size of approxi-
mately 29,000 patients.
Observational Studies
Eight observational studies were deemed eligible. Supplemen-
tal Tables 6 and 7 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425) describe the patient characteristics 
and results of the quality assessments. Six studies were high 
quality; two, low quality.
A total of 2,058 septic patients (six studies) were included 
in the analysis of 28-day/hospital mortality; 15,374 septic 
patients (two studies) were included in the analysis of early 
mortality. Outcome data for the individual studies, includ-
ing adjusted and unadjusted ORs for mortality, are shown 
in Supplemental Table 8 (Supplemental Digital Content 5, 
http://links.lww.com/CCM/C425). The pooled OR for 28-day/
hospital mortality was 0.90 (95% CI, 0.54–1.51; I2 = 76.1%) 
(Fig. 2). The pooled OR for early mortality was 0.22 (95% CI, 
0.004–13.14; I2 = 86.7%) (Supplemental Fig. 1, Supplemental 
Digital Content 5, http://links.lww.com/CCM/C425). Other 
secondary outcomes were not reported in a sufficient number 
of studies to be analyzed. No specific antipyretic method was 
significantly associated with mortality benefit, and stratifica-
tion by study quality did not yield results that differed from 
the overall pooled OR (Table 1). Publication bias was not evi-
dent (Egger test, p = 0.54). (Supplemental Fig. 4, Supplemental 
Digital Content 5, http://links.lww.com/CCM/C425).
DISCUSSION
Despite lack of evidence showing benefit of antipyretic ther-
apy in septic patients, treatment of fever is ubiquitous in the 
ICU (14). This meta-analysis was undertaken to inform clini-
cal practice by assessing outcomes associated with antipyretic 
therapy. The results demonstrate that, while associated with a 
reduction in body temperature, antipyretic therapy does not 
confer a 28-day/hospital mortality benefit in septic patients. 
Secondary outcomes, including shock reversal and acquisi-
tion of nosocomial infections, were also unaffected by anti-
pyretic treatments. Consistency in results was demonstrated 
across study design as well as in a priori subgroup and strati-
fied analyses. Furthermore, the extended funnel plot analysis 
suggests that these results are likely to be robust to the impact 
of an additional trial in the future; none of the existing stud-
ies generated an effect size-se combination that could change 
the pooled RR to favor antipyretic treatment. Additionally, 
simulation analysis showed that to achieve a reasonable power 
to change the meta-analysis results, an additional trial would 
need to enroll tens of thousands of patients. Based on the sam-
ple sizes and enrollment durations of the existing multicenter 
studies, a trial of this size seems unfeasible.
Interestingly, early mortality (occurring within 14 d or 
during ICU stay) was significantly lower in patients treated 
with antipyretic therapy in the randomized studies. This out-
come was analyzed separately from 28-day/hospital mortality 
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TABLE 1. Summary of Meta-Analysis Results
Analysis
Randomized Studies Observational Studies




Relative Risk  
(95% CI) or Mean  
Difference  
(95% CI) P I2, %
No. of  
Studies
Sample 
Size OR (95% CI) P I2, %
Primary outcome  
 28-d/hospital mortality 8 1,507 0.93 (0.79–1.09) 0.36 0.0 6 2,058 0.90 (0.54–1.51) 0.70 76.1
  28-d mortality 4 1,198 0.93 (0.77–1.13) 0.49 0.0 — — — — —
  Febrile patients 5 1,341 0.96 (0.80–1.14) 0.60 0.0 4 1160 0.59 (0.32–1.07) 0.08 48.5
  Patients with shock 2a 493 0.91 (0.74–1.11) 0.34 0.0 — — — — —
  High-quality studiesb 5 1,238 0.93 (0.76–1.12) 0.43 0.0 5 2028 0.99 (0.62–1.60) 0.98 74.0
Secondary outcomes  
 Early mortality (≤ 14 d/ICU) 4 960 0.68 (0.49–0.92) 0.01 0.0 2 15,374 1.35 (1.15–1.59) < 0.001 0.0
 Frequency of nosocomial 
infections
3c 684 1.13 (0.61–2.09) 0.69 61.0 — — — — —
 Shock reversal 3 232 1.13 (0.68–1.90) 0.63 51.6 — — — — —
 Postintervention  
temperature (°C)
8 1,510 –0.38 (–0.63 to –0.13) < 0.003 84.0 — — — — —
 Postintervention heart rate 
(beats/min)
5 594 –4.2 (–10.2 to 1.9) 0.18 42.9 — — — — —
 Postintervention minute 
ventilation (L/min)
3 514 –0.10 (–1.15 to 0.94) 0.85 0.0 — — — — —
Stratified analyses  
 28-d/hospital mortality  
by intervention type
 
  Acetaminophen 3 753 0.93 (0.68–1.40) 0.90 0.0 5d 2028 0.81 (0.46–1.42) 0.46 74.6
  NSAID 4 554 0.94 (0.68–1.31) 0.72 17.4 1 606 2.61 (1.11–6.12) 0.03 —
  Physical cooling 1 200 0.88 (0.65–1.19) 0.40 — 2 636 0.20 (0.00–10.91) 0.43 85.5
 28-d/hospital mortality  
by treatment goal
 
  Anti-inflammatory treatment 5 594 0.92 (0.66–1.28) 0.61 15.4 1 292 0.48 (0.25–0.92) 0.03 —
  Fever treatment 3 913 0.93 (0.74–1.18) 0.55 0.0 5 1,766 1.00 (0.57–1.75) 0.99 75.7
 28-d/hospital mortality  
by treatment duration
 
  ≥ ICU length of stay 2 713 1.01 (0.70–1.46) 0.95 0.0 2 1,287 1.37 (0.75–2.50) 0.31 77.1
  < ICU length of stay 6 794 0.91 (0.77–1.08) 0.29 0.0 4 771 0.51 (0.26–0.98) 0.05 47.6
 Postintervention temperature  
by intervention type
 
  Acetaminophen 3 756 –0.14 (–0.37 to 0.10) 0.26 71.3 — — — — —
  NSAID 4 554 –0.59 (–1.16 to –0.03) 0.04 85.4 — — — — —
  Physical cooling 1 200 –0.80 (–1.06 to –0.54)< 0.001 — — — — — —
NSAID = nonsteroidal anti-inflammatory drug, OR = odds ratio.
a Memiş et al (41) excluded from analysis (100% mortality in both arms).
b Randomized studies with a high or unclear risk of bias in less than two domains on the Cochran Collaboration Risk of Bias Tool or observational studies with a 
Newcastle-Ottawa Scale score greater than 7 were considered to be high quality.
c Niven et al (42) excluded from analysis (0 nosocomial infections in septic patients in both arms).
d The two studies by Mohr et al (46, 47) were analyzed in the acetaminophen subgroup due to the reported low use of nonsteroidal anti-inflammatory drugs in 
those studies.
Dashes indicate insufficient data to analyze.
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because several studies reported 14-day/ICU mortality rates 
that differed from those at later time points (26, 27). The 
importance of improved early mortality, though, is question-
able as a patient-centered outcome, and this finding should not 
influence clinical practice. One hypothesis for the decrease in 
early, but not later, deaths is that fever treatment blunts the 
immunologic benefit of hyperthermia leading to increased 
nosocomial infections later in the hospital course. The results 
of this meta-analysis demonstrated no significant differences 
in the acquisition of nosocomial infections among patients 
who did and did not receive antipyretic therapy. Analysis of 
this outcome, however, included only three studies, so evidence 
is limited. This may be an area for future study.
Proponents of fever treatment advocate that the chief ben-
efit of antipyretic therapy in critically ill patients is a reduction 
of the metabolic burden typi-
cally associated with elevated 
body temperature (50). This 
meta-analysis shows that 
although antipyretic therapy 
is effective in decreasing 
body temperature, heart rate 
and minute ventilation are 
less affected. Also, antipyre-
sis did not improve mortality 
in the subgroup of patients 
with septic shock, who pre-
sumably would be the most 
likely to benefit from a reduc-
tion in metabolic burden. 
These results suggest that the 
potential physiologic benefit 
of antipyretic therapies may 
be overstated and does not 
translate into improvement 
in outcomes.
Definitions of fever 
ranged from a body tempera-
ture of 38.0°C to 38.4°C in 
the randomized studies and 
from 37.3°C to 39.5°C in the 
observational studies. The 
larger range of fever defini-
tions in the observational 
studies may have contributed 
(along with other factors 
such as variations in study 
design, patient population, 
and analysis techniques) to 
the greater heterogeneity 
observed in the meta-analysis 
results. Of note, the observa-
tional study with the highest 
threshold for fever treatment 
(39.5°C) demonstrated the 
most substantial improve-
ment in 28-day/hospital mortality with antipyretic therapy 
(44). The implication of this finding is unclear, though, because 
of this study’s small sample size, methodologic limitations, and 
unique method of physical cooling (continuous venovenous 
hemofiltration).
This meta-analysis has important limitations. Many of stud-
ies included in the analysis were not designed primarily to eval-
uate the clinical effect of fever treatment but rather the effect of 
specific anti-inflammatory actions of the interventions being 
studied. Thus, both febrile and afebrile patients were enrolled, 
and administration of other antipyretics beyond the specific 
therapy being studied was not controlled. To address this 
limitation, analysis of the primary outcome was stratified by 
the goal of the study (evaluation of anti-inflammatory treat-
ment vs evaluation of fever treatment) and a subgroup analysis 
A
B
Figure 2. Results of meta-analysis for 28 days per hospital mortality in (A) randomized studies and (B) 
observational studies. A relative risk (RR) or odds ratio (OR) less than 1 favors antipyretic therapy. The size of the 
grey box corresponds to weight in the random effects analysis. NSAID = nonsteroidal anti-inflammatory drug.
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including only febrile patients was performed. The results of 
these analyses were virtually identical to the pooled RR and 
95% CI reported for the entire cohort indicating that this limi-
tation should not significantly affect the overall conclusions of 
this meta-analysis.
The studies included in this meta-analysis also varied 
considerably in terms of the specific antipyretic interven-
tions being evaluated (NSAIDs, acetaminophen, physical 
cooling) and the duration of antipyretic treatment. Each 
intervention is associated with distinct effects beyond fever 
control which could potentially affect patient outcomes. 
Despite this, study heterogeneity was low (I2 = 0.0%) in the 
randomized studies, and stratified analysis did not show 
significant differences in mortality among different inter-
vention types or intervention durations. However, since 
fewer studies were analyzed in each stratum as compared to 
the overall meta-analysis, it is possible that future studies of 
specific treatments would have more power to change these 
stratified results at any given sample size than indicated by 
our sample size simulation analysis.
Additionally, although the search was the most rigorous 
and comprehensive one on this topic to date, several studies 
that included mixed populations of infected and noninfected 
patients were excluded because mortality data could not be 
obtained for the subset of infected patients. Based on the 
extended funnel plot and the power curve generated from sim-
ulated sample size calculations, the inclusion of these studies 
would not have changed the results of the primary outcome.
Finally, sepsis is a heterogeneous syndrome by definition. 
Although our results strongly suggest that antipyretic therapy, 
across a broad cohort of septic patients, does not improve out-
come, it is unable to inform on the individual septic patient 
who may accrue benefit from fever control.
CONCLUSIONS
Antipyretic treatment does not significantly improve 28-day/
hospital mortality in adult patients with sepsis. Additional 
studies are unlikely to be powered sufficiently to change this 
conclusion.
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